Analyst Research Report Snapshot

Title:

VERNALIS - R&D UPDATE

Price:

$10.00

Provider:

Edison Investment Research

Date:

14 Dec 2009

Pages:

8

Type:

AcrobatPDF

Companies referenced:

VER.L

Available for Immediate Download
Summary:

Vernalis’s partner Novartis has confirmed plans to progress the HSP90 inhibitor AUY922 into a proof of concept Phase II study in 2010, an event which triggers a milestone payment. Although expected, the confirmation is nonetheless encouraging, particularly as both AUY922 and the earlier stage HSP990 project feature well among a wider investor presentation on Novartis’s oncology programmes. FOR MORE INFORMATION ON THE ATTACHED RESEARCH PLEASE CALL 020 3077 5700, EMAIL RESEARCH@EDISONINVESTMENTRESEARCH.CO.UK OR VISIT WWW.EDISONINVESTMENTRESEARCH.CO.UK

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.